Roth Capital Predicts Journey Medical FY2024 Earnings

Journey Medical Co. (NASDAQ:DERM) – Investment analysts at Roth Capital decreased their FY2024 earnings per share estimates for shares of Journey Medical in a research report issued on Monday, November 18th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($1.00) for the year, down from their previous forecast of ($0.93). The consensus estimate for Journey Medical’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.09 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

A number of other equities analysts also recently issued reports on DERM. Lake Street Capital assumed coverage on Journey Medical in a research note on Friday, September 6th. They set a “buy” rating and a $9.00 price target for the company. Rodman & Renshaw initiated coverage on shares of Journey Medical in a research report on Thursday, August 22nd. They set a “buy” rating and a $9.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.38.

Journey Medical Price Performance

DERM stock opened at $5.20 on Thursday. The company has a market capitalization of $107.80 million, a P/E ratio of -5.56 and a beta of 0.92. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a 52-week low of $2.85 and a 52-week high of $8.11. The business has a 50-day simple moving average of $5.64 and a two-hundred day simple moving average of $5.09.

Hedge Funds Weigh In On Journey Medical

Several hedge funds have recently modified their holdings of the company. Nwam LLC bought a new stake in shares of Journey Medical in the 3rd quarter worth approximately $59,000. TMD Wealth Management LLC bought a new stake in shares of Journey Medical in the 2nd quarter worth approximately $65,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Journey Medical in the 3rd quarter worth approximately $66,000. ORG Wealth Partners LLC bought a new stake in shares of Journey Medical in the 3rd quarter worth approximately $110,000. Finally, Geode Capital Management LLC raised its holdings in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after purchasing an additional 12,882 shares during the period. Institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.